•  
  •  
 

Abstract

Oral colon-targeted drug delivery systems represent a significant advancement offering both systemic and local therapeutic effects for a range of intestinal diseases, including irritable bowel syndrome, inflammatory bowel disease, colonic bacterial infections, and colorectal cancer. These systems facilitate the delivery of both small molecules and macromolecular compounds such as peptides, proteins, antibodies, oligonucleotides, RNA, and probiotics. This review provides an up-to-date exploration of the critical factors crucial for the effective design and development of drug delivery systems targeting the colon. The chosen strategy takes into account various aspects of colon physiology that influences the profile of drug release, absorption, dissolution, and stability in the colon, including pH, retention time, presence of enzymes, pressure, presence of reactive oxygen species due to inflammation, and specific receptors. Site-targeted drug release allows for high concentrations in the colon while minimizing systemic adverse effects by reducing or preventing drug absorption in the small intestine.

References

Abraham, C., & Cho, J. H. (2009). Inflammatory bowel disease. New England Journal of Medicine, 361(21), 2066–2078. https://doi.org/10.1056/NEJMra0804647

Alange, V. V., Birajdar, R. P., & Kulkarni, R. V. (2017). Functionally modified polyacrylamide- graft -gum karaya pH-sensitive spray dried microspheres for colon targeting of an anti-cancer drug. International Journal of Biological Macromolecules, 102, 829–839. https://doi. org/10.1016/j.ijbiomac.2017.04.023

Amidon, S., Brown, J. E., & Dave, V. S. (2015). Colon- targeted oral drug delivery systems: Design trends and approaches. AAPS PharmSciTech, 16(4), 731–741. https://doi.org/10.1208/s12249-015-0350-9

Awad, A., Madla, C. M., McCoubrey, L. E., Ferraro, F., Gavins, F. K. H., Buanz, A., Gaisford, S., Orlu, M., Siepmann, F., Siepmann, J., & Basit, A. W. (2022). Clinical translation of advanced colonic drug delivery technologies. In Advanced Drug Delivery Reviews (Vol. 181). Elsevier B.V. https://doi.org/10.1016/j. addr.2021.114076

Babu, A., Yadav, J. S., Gupta, D., & Gupta, A. (2022). Recent advancement in colon-specific drug delivery system: An overview. Journal of Pharmaceutical Negative Results, 13(7). https://doi.org/10.47750/ pnr.2022.13.S07.961

Bak, A., Ashford, M., & Brayden, D. J. (2018). Local delivery of macromolecules to treat diseases associated with the colon. Advanced Drug Delivery Reviews, 136– 137, 2–27. https://doi.org/10.1016/j.addr.2018.10.009

Banerjee, A., Pathak, S., Subramanium, V. D., G., D., Murugesan, R., & Verma, R. S. (2017). Strategies for targeted drug delivery in treatment of colon cancer: current trends and future perspectives. Drug Discovery Today, 22(8), 1224–1232. https://doi.org/10.1016/j. drudis.2017.05.006

Barclay, T. G., Day, C. M., Petrovsky, N., & Garg, S. (2019). Review of polysaccharide particle-based functional drug delivery. Carbohydrate Polymers, 221, 94–112. https://doi.org/10.1016/j.carbpol.2019.05.067

Baumgart, D. C. (2008). What’s new in inflammatory bowel disease in 2008? World Journal of Gastroenterology, 14(3), 329. https://doi.org/10.3748/ wjg.14.329

Bazan, L., Bendas, E. R., El Gazayerly, O. N., & Badawy, S. S. (2016). Comparative pharmaceutical study on colon targeted micro-particles of celecoxib: in-vitro–in-vivo evaluation. Drug Delivery, 23(9), 3339–3349. https://doi.org/10.1080/10717544.2016.1178824

Belali, N., Wathoni, N., & Muchtaridi, M. (2019). Advances in orally targeted drug delivery to colon. Journal of Advanced Pharmaceutical Technology & Research, 10(3), 100. https://doi.org/10.4103/japtr. JAPTR_26_19

Bharadwaj, S., Barber, M. D., Graff, L. A., & Shen, B. (2015). Symptomatology of irritable bowel syndrome and inflammatory bowel disease during the menstrual cycle. Gastroenterology Report, 3(3), 185–193. https:// doi.org/10.1093/gastro/gov010

Bhaskaran, N. A., & Kumar, L. (2021). Treating colon cancers with a non-conventional yet strategic approach: An overview of various nanoparticulate systems. Journal of Controlled Release, 336, 16–39. https://doi. org/10.1016/j.jconrel.2021.06.008

Dinning, P. G., Wiklendt, L., Maslen, L., Gibbins, I., Patton, V., Arkwright, J. W., Lubowski, D. Z., O’Grady, G., Bampton, P. A., Brookes, S. J., & Costa, M. (2014). Quantification of in vivo colonic motor patterns in healthy humans before and after a meal revealed by high-resolution fiber-optic manometry. Neurogastroenterology and Motility, 26(10), 1443–1457. https://doi.org/10.1111/nmo.12408

Dugad, A., Nalawade, P., Thakhre, R., & Kakade, S. (2018). Colon targeted drug delivery system-A review. Curr. Pharm. Res, 9(1), 2604–2635. www.jcpronline.in/

Edsbacker, S., & Andersson, T. (2004). Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn’s disease. Clinical Pharmacokinetics, 43(12), 803–821. https://doi.org/10.2165/00003088-200443120-00003

Ferri, D., Gaviña, P., Parra, M., Costero, A. M., El Haskouri, J., Amorós, P., Merino, V., Teruel, A. H., Sancenón, F., & Martínez-Máñez, R. (2018). Mesoporous silica microparticles gated with a bulky azo derivative for the controlled release of dyes/drugs in colon. Royal Society Open Science, 5(8), 180873. https:// doi.org/10.1098/rsos.180873

Fletcher, S. M., McLaws, M.-L., & Ellis, J. T. (2013). Prevalence of gastrointestinal pathogens in developed and developing countries: Systematic review and meta- analysis. Journal of Public Health Research, 2(1), jphr.2013.e9. https://doi.org/10.4081/jphr.2013.e9

Foppoli, A., Maroni, A., Moutaharrik, S., Melocchi, A., Zema, L., Palugan, L., Cerea, M., & Gazzaniga, A. (2019). In vitro and human pharmacoscintigraphic evaluation of an oral 5-ASA delivery system for colonic release. International Journal of Pharmaceutics, 572, 118723. https://doi.org/10.1016/j.ijpharm.2019.118723

Friend, D. R. (2005). New oral delivery systems for treatment of inflammatory bowel disease. Advanced Drug Delivery Reviews, 57(2), 247–265. https://doi. org/10.1016/j.addr.2004.08.011

Gabizon, A. A. (2001). Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Cancer Investigation, 19(4), 424–436. https://doi.org/10.1081/CNV-100103136

Gareb, B., Dijkstra, G., Kosterink, J. G. W., & Frijlink, H. W. (2019). Development of novel zero-order release budesonide tablets for the treatment of ileo- colonic inflammatory bowel disease and comparison with formulations currently used in clinical practice. International Journal of Pharmaceutics, 554, 366–375. https://doi.org/10.1016/j.ijpharm.2018.11.019

Goll, R., Johnsen, P. H., Hjerde, E., Diab, J., Valle, P. C., Hilpusch, F., & Cavanagh, J. P. (2020). Effects of fecal microbiota transplantation in subjects with irritable bowel syndrome are mirrored by changes in gut microbiome. Gut Microbes, 12(1), 1794263. https://doi. org/10.1080/19490976.2020.1794263

Grifantini, R., Taranta, M., Gherardini, L., Naldi, I., Parri, M., Grandi, A., Giannetti, A., Tombelli, S., Lucarini, G., Ricotti, L., Campagnoli, S., De Camilli, E., Pelosi, G., Baldini, F., Menciassi, A., Viale, G., Pileri, P., & Cinti, C. (2018). Magnetically driven drug delivery systems improving targeted immunotherapy for colon- rectal cancer. Journal of Controlled Release, 280, 76–86. https://doi.org/10.1016/j.jconrel.2018.04.052

Grover, m., Kanazawa, m., Palsson, o. s., Chitkara, d. k., Gangarosa, l. m., Drossman, d. a., & Whitehead, w. e. (2008). Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, and psychological distress. Neurogastroenterology & Motility, 20(9), 998–1008. https://doi.org/10.1111/j.1365-2982.2008.01142.x

Hadi, M. A., Raghavendra Rao, N. G., Srinivasa Rao, A., Mahtab, T., & Tabassum, S. (2018). A review on various formulation methods in preparing Colon targeted mini-tablets for chronotherapy. Journal of Applied Pharmaceutical Science (Vol. 8, Issue 3, pp. 158–164). Open Science Publishers LLP Inc. https://doi. org/10.7324/JAPS.2018.8321

Handali, S., Moghimipour, E., Rezaei, M., Ramezani, Z., Kouchak, M., Amini, M., Angali, K. A., Saremy, S., & Dorkoosh, F. A. (2018). A novel 5-Fluorouracil targeted delivery to colon cancer using folic acid conjugated liposomes. Biomedicine & Pharmacotherapy, 108, 1259– 1273. https://doi.org/10.1016/j.biopha.2018.09.128

Hou, L., Shi, Y., Jiang, G., Liu, W., Han, H., Feng, Q., Ren, J., Yuan, Y., Wang, Y., Shi, J., & Zhang, Z. (2016). Smart nanocomposite hydrogels based on azo crosslinked graphene oxide for oral colon-specific drug delivery. Nanotechnology, 27(31), 315105. https://doi. org/10.1088/0957-4484/27/31/315105

Huang, Y., Canup, B. S. B., Gou, S., Chen, N., Dai, F., Xiao, B., & Li, C. (2021). Oral nanotherapeutics with enhanced mucus penetration and ROS-responsive drug release capacities for delivery of curcumin to colitis tissues. Journal of Materials Chemistry B, 9(6), 1604– 1615. https://doi.org/10.1039/d0tb02092c

Huang, Z., Gan, J., Jia, L., Guo, G., Wang, C., Zang, Y., Ding, Z., Chen, J., Zhang, J., & Dong, L. (2015). An orally administrated nucleotide-delivery vehicle targeting colonic macrophages for the treatment of inflammatory bowel disease. Biomaterials, 48, 26–36. https://doi.org/10.1016/j.biomaterials.2015.01.013

Ibekwe, V. C., Liu, F., Fadda, H. M., Khela, M. K., Evans, D. F., Parsons, G. E., & Basit, A. W. (2006). An investigation into the in vivo performance variability of pH responsive polymers for ileo-colonic drug delivery using gamma scintigraphy in humans. Journal of Pharmaceutical Sciences, 95(12), 2760–2766. https:// doi.org/10.1002/jps.20742

Ibrahim, I. M. (2023). Advances in polysaccharide-Based oral colon-targeted delivery systems: The journey so far and the road ahead. Cureus. https://doi.org/10.7759/ cureus.33636

Iswandana, R., Mutia, M. P., & Widyaningrum, F. K. (2018). Unsuccessful delivery of tetrandrine from colon-targeted dosage forms comprising alginate/ hydroxypropyl methylcellulose and alginate-chitosan beads. International Journal of Applied Pharmaceutics, 10(1).

Iswandana, R., Putri, K. S. S., Dwiputra, R., Yanuari, T., Sari, S. P., & Djajadisastra, J. (2017). Formulation of chitosan tripolyphosphate-tetrandrine beads using ionic gelation method: In vitro and in vivo evaluation. International Journal of Applied Pharmaceutics, 9(5), 109–115. https://doi.org/10.22159/ijap.2017v9i5.20842

Iswandana, R., Putri, K. S. S., Sandiata, C. E., Triani, S., Sari, S. P., & Djajadisastra, J. (2017). Formulation of tetrandrine beads using ionic gelation method CA- pectinate coated PH-sensitive polymers as colon- targeted dosage form. Asian Journal of Pharmaceutical and Clinical Research, 10(10), 90–95. https://doi. org/10.22159/ajpcr.2017.v10i10.19994

Iswandana, R., Putri, K. S. S., Wulandari, F. R., Najuda, G., Sari, S. P., & Djajadisastra, J. (2018). Preparation of calcium alginate-tetrandrine beads using ionic gelation method as colon-targeted dosage form. Journal of Applied Pharmaceutical Science, 8(5), 68–74. https:// doi.org/10.7324/JAPS.2018.8509

Iswandana, R., Sutriyo, S., Gunawan, M., Larasati, S. A., & Putri, F. A. (2021). Colon-targeted protein delivery by using solid lipid nanoparticles. Journal of Applied Pharmaceutical Science, 11(9), 118–123. https://doi. org/10.7324/JAPS.2021.110914

Iyengar, K. R., Komala, M., & Satheeshkumar, S. (2020). Colon specific drug delivery systems – Different systems and approaches: A review. Research Journal of Pharmacy and Technology (Vol. 13, Issue 12, pp. 6248– 6258). Research Journal of Pharmacy and Technology. https://doi.org/10.5958/0974-360X.2020.01089.6

Jornada, D. H., Dos Santos Fernandes, G. F., Chiba, D. E., De Melo, T. R. F., Dos Santos, J. L., & Chung, M. C. (2016). The prodrug approach: A successful tool for improving drug solubility. In Molecules (Vol. 21, Issue 1). MDPI AG. https://doi.org/10.3390/molecules21010042

Katsuma, M., Watanabe, S., Takemura, S., Sako, K., Sawada, T., Masuda, Y., Nakamura, K., Fukui, M., Connor, A. L., & Wilding, I. R. (2004). Scintigraphic evaluation of a novel colon-targeted delivery system (CODESTM) in healthy volunteers. Journal of Pharmaceutical Sciences, 93(5), 1287–1299. https://doi. org/10.1002/jps.20063

Kesisoglou, F., & Zimmermann, E. M. (2005). Novel drug delivery strategies for the treatment of inflammatory bowel disease. Expert Opinion on Drug Delivery, 2(3), 451–463. https://doi.org/10.1517/17425247.2.3.451

Kim, S., Lee, S., Lee, H., Ju, S., Park, S., Kwon, D., Yoo, J. W., Yoon, I. S., Min, D. S., Jung, Y. S., & Jung, Y. (2020). A colon-targeted prodrug, 4-phenylbutyric acid-glutamic acid conjugate, ameliorates 2,4-dinitrobenzenesulfonic acid-induced colitis in rats. Pharmaceutics, 12(9), 1–16. https://doi.org/10.3390/pharmaceutics12090843

Kumar, P., Iftekhar Ahmad, M., Aggarwal, D., Chand Bala, V., & Kumari, M. (2019). Novel drug delivery carrier system:- A updated review. Article in World Journal of Pharmaceutical Research, 8. https://doi. org/10.20959/wjpr201911-15880

Kumar, R., Islam, T., & Nurunnabi, M. (2022). Mucoadhesive carriers for oral drug delivery. Journal of Controlled Release (Vol. 351, pp. 504–559). Elsevier B.V. https://doi.org/10.1016/j.jconrel.2022.09.024

Kurakula, M., Gorityala, S., & Moharir, K. (2021). Recent trends in design and evaluation of chitosan- based colon targeted drug delivery systems: Update 2020. Journal of Drug Delivery Science and Technology (Vol. 64). Editions de Sante. https://doi.org/10.1016/j. jddst.2021.102579

Labianca, R., Beretta, G. D., Kildani, B., Milesi, L., Merlin, F., Mosconi, S., Pessi, M. A., Prochilo, T., Quadri, A., Gatta, G., de Braud, F., & Wils, J. (2010). Colon cancer. Critical Reviews in Oncology/ Hematology, 74(2), 106–133. https://doi.org/10.1016/j. critrevonc.2010.01.010

Langhorst, J., Junge, A., Rueffer, A., Wehkamp, J., Foell, D., Michalsen, A., Musial, F., & Dobos, G. J. (2009). Elevated human β-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. The American Journal of Gastroenterology, 104(2), 404–410. https://doi. org/10.1038/ajg.2008.86

Lee, S. H., Bajracharya, R., Min, J. Y., Han, J. W., Park, B. J., & Han, H. K. (2020). Strategic approaches for colon targeted drug delivery: An overview of recent advancements. In Pharmaceutics (Vol. 12, Issue 1). MDPI AG. https://doi.org/10.3390/pharmaceutics12010068

Lemmens, G., Van Camp, A., Kourula, S., Vanuytsel, T., & Augustijns, P. (2021). Drug disposition in the lower gastrointestinal tract: Targeting and monitoring. In Pharmaceutics (Vol. 13, Issue 2). MDPI AG. https://doi. org/10.3390/pharmaceutics13020161

Lin, C., Ng, H., Pan, W., Chen, H., Zhang, G., Bian, Z., Lu, A., & Yang, Z. (2015). Exploring different strategies for efficient delivery of colorectal cancer therapy. International Journal of Molecular Sciences, 16(11), 26936–26952. https://doi.org/10.3390/ijms161125995

Liu, F., Moreno, P., & Basit, A. W. (2010). A novel double-coating approach for improved pH-triggered delivery to the ileo-colonic region of the gastrointestinal tract. European Journal of Pharmaceutics and Biopharmaceutics, 74(2), 311–315. https://doi. org/10.1016/j.ejpb.2009.11.008

Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006). Functional bowel disorders. Gastroenterology, 130(5), 1480–1491. https://doi.org/10.1053/j.gastro.2005.11.061

Lou, J., Duan, H., Qin, Q., Teng, Z., Gan, F., Zhou, X., & Zhou, X. (2023). Advances in oral drug delivery systems: Challenges and opportunities. In Pharmaceutics (Vol. 15, Issue 2). MDPI. https://doi.org/10.3390/ pharmaceutics15020484

Maroni, A., Moutaharrik, S., Zema, L., & Gazzaniga, A. (2017). Enteric coatings for colonic drug delivery: state of the art. Expert Opinion on Drug Delivery, 14(9), 1027–1029. https://doi.org/10.1080/17425247.2017.1360864

Maroni, A., Zema, L., Loreti, G., Palugan, L., & Gazzaniga, A. (2013). Film coatings for oral pulsatile release. International Journal of Pharmaceutics, 457(2), 362–371. https://doi.org/10.1016/j.ijpharm.2013.03.010

McCoubrey, L. E., Favaron, A., Awad, A., Orlu, M., Gaisford, S., & Basit, A. W. (2023). Colonic drug delivery: Formulating the next generation of colon- targeted therapeutics. In Journal of Controlled Release (Vol. 353, pp. 1107–1126). Elsevier B.V. https://doi. org/10.1016/j.jconrel.2022.12.029

Melero, A., Draheim, C., Hansen, S., Giner, E., Carreras, J. J., Talens-Visconti, R., Garrigues, T. M., Peris, J. E., Recio, M. C., Giner, R., & Lehr, C.-M. (2017). Targeted delivery of cyclosporine A by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model. European Journal of Pharmaceutics and Biopharmaceutics, 119, 361–371. https://doi.org/10.1016/j.ejpb.2017.07.004

Naeem, M., Bae, J., A. Oshi, M., Kim, M.-S., Moon, H. R., Lee, B. L., Im, E., Jung, Y., & Yoo, J.-W. (2018). Colon-targeted delivery of cyclosporine a using dual-functional Eudragit® FS30D/PLGA nanoparticles ameliorates murine experimental colitis. International Journal of Nanomedicine, Volume 13, 1225–1240. https://doi.org/10.2147/IJN.S157566

Nidhi, Rashid, M., Kaur, V., Hallan, S. S., Sharma, S., & Mishra, N. (2016). Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review. Saudi Pharmaceutical Journal, 24(4), 458–472. https://doi.org/10.1016/j.jsps.2014.10.001

Ordás, I., Eckmann, L., Talamini, M., Baumgart, D. C., & Sandborn, W. J. (2012). Ulcerative colitis. The Lancet, 380(9853), 1606–1619. https://doi.org/10.1016/S0140-6736(12)60150-0

Oshi, M. A., Naeem, M., Bae, J., Kim, J., Lee, J., Hasan, N., Kim, W., Im, E., Jung, Y., & Yoo, J.-W. (2018). Colon-targeted dexamethasone microcrystals with pH- sensitive chitosan/alginate/Eudragit S multilayers for the treatment of inflammatory bowel disease. Carbohydrate Polymers, 198, 434–442. https://doi.org/10.1016/j. carbpol.2018.06.107

Patel, M. M. (2011). Cutting-edge technologies in colon- targeted drug delivery systems. Expert Opinion on Drug Delivery, 8(10), 1247–1258. https://doi.org/10.1517/17425247.2011.597739

Pimentel, M., Chang, C., Chua, K. S., Mirocha, J., DiBaise, J., Rao, S., & Amichai, M. (2014). Antibiotic treatment of constipation-predominant irritable bowel syndrome. Digestive Diseases and Sciences, 59(6), 1278–1285. https://doi.org/10.1007/s10620-014-3157-8

Porter, R. J., Kalla, R., & Ho, G.-T. (2020). Ulcerative colitis: Recent advances in the understanding of disease pathogenesis. F1000Research, 9, 294. https://doi. org/10.12688/f1000research.20805.1

Qiao, H., Fang, D., Chen, J., Sun, Y., Kang, C., Di, L., Li, J., Chen, Z., Chen, J., & Gao, Y. (2017). Orally delivered polycurcumin responsive to bacterial reduction for targeted therapy of inflammatory bowel disease. Drug Delivery, 24(1), 233–242. https://doi.org/10.1080/10717544.2016.1245367

Rathbone, M. J., Hadgraft, J., & Roberts, M. S. (2003). Modified-release Drug Delivery Technology. Marcel Dekker.

Rizzello, F., Gionchetti, P., D’Arienzo, A., Manguso, F., Di Matteo, G., Annese, V., Valpiani, D., Casetti, T., Adamo, S., Prada, A., Castiglione, G. N., Varoli, G., & Campieri, M. (2002). Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Alimentary Pharmacology & Therapeutics, 16(6), 1109–1116. https://doi.org/10.1046/ j.1365-2036.2002.01298.x

Sardo, S. H., Saremnejad, F., Bagheri, S., Akhgari, A., Afrasiabi Garekani, H., & Sadeghi, F. (2019). A review on 5-aminosalicylic acid colon-targeted oral drug delivery systems. In International Journal of Pharmaceutics (Vol. 558, pp. 367–379). Elsevier B.V. https://doi.org/10.1016/j.ijpharm.2019.01.022

Sinha, V. R., & Kumria, R. (2001). Polysaccharides in colon-specific drug delivery. International Journal of Pharmaceutics, 224(1–2), 19–38. https://doi. org/10.1016/S0378-5173(01)00720-7

Sousa, T., Yadav, V., Zann, V., Borde, A., Abrahamsson, B., & Basit, A. W. (2014). On the colonic bacterial metabolism of azo-bonded prodrugs of 5-aminosalicylic acid. Journal of Pharmaceutical Sciences, 103(10), 3171–3175. https://doi.org/10.1002/jps.24103

Sun, Q., Luan, L., Arif, M., Li, J., Dong, Q.-J., Gao, Y., Chi, Z., & Liu, C.-G. (2018). Redox-sensitive nanoparticles based on 4-aminothiophenol-carboxymethyl inulin conjugate for budesonide delivery in inflammatory bowel diseases. Carbohydrate Polymers, 189, 352–359. https://doi.org/10.1016/j.carbpol.2017.12.021

Teruel, A. H., Gonzalez-Alvarez, I., Bermejo, M., Merino, V., Marcos, M. D., Sancenon, F., Gonzalez-Alvarez, M., & Martinez-Mañez, R. (2020). New insights of oral colonic drug delivery systems for inflammatory bowel disease therapy. In International Journal of Molecular Sciences (Vol. 21, Issue 18, pp. 1–30). MDPI AG. https:// doi.org/10.3390/ijms21186502

Teruel, A. H., Pérez-Esteve, É., González-Álvarez, I., González-Álvarez, M., Costero, A. M., Ferri, D., Parra, M., Gaviña, P., Merino, V., Martínez-Mañez, R., & Sancenón, F. (2018). Smart gated magnetic silica mesoporous particles for targeted colon drug delivery: New approaches for inflammatory bowel diseases treatment. Journal of Controlled Release, 281, 58–69. https://doi.org/10.1016/j.jconrel.2018.05.007

Varum, F. J. O., Hatton, G. B., Freire, A. C., & Basit, A. W. (2013). A novel coating concept for ileo-colonic drug targeting: Proof of concept in humans using scintigraphy. European Journal of Pharmaceutics and Biopharmaceutics, 84(3), 573–577. https://doi. org/10.1016/j.ejpb.2013.01.002

Wahlgren, M., Axenstrand, M., Håkansson, Å., Marefati, A., & Pedersen, B. L. (2019). In vitro methods to study colon release: State of the art and an outlook on new strategies for better in-vitro biorelevant release media. In Pharmaceutics (Vol. 11, Issue 2). MDPI AG. https://doi. org/10.3390/pharmaceutics11020095

Wang, D., Wang, W., Wang, P., Wang, C., Niu, J., Liu, Y., & Chen, Y. (2023). Research progress of colon-targeted oral hydrogel system based on natural polysaccharides. In International Journal of Pharmaceutics (Vol. 643). Elsevier B.V. https://doi.org/10.1016/j. ijpharm.2023.123222

Wang, J.-L., Gan, Y.-J., Iqbal, S., Jiang, W., Yuan, Y.-Y., & Wang, J. (2018). Delivery of tacrolimus with cationic lipid-assisted nanoparticles for ulcerative colitis therapy. Biomaterials Science, 6(7), 1916–1922. https://doi. org/10.1039/C8BM00463C

Wiwattanapatapee, R., Lomlim, L., & Saramunee, K. (2003). Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid. Journal of Controlled Release, 88(1), 1–9. https://doi.org/10.1016/S01683659(02)00461-3

Yasmin, F., Najeeb, H., Shaikh, S., Hasanain, M., Naeem, U., Moeed, A., Koritala, T., Hasan, S., & Surani, S. (2022). Novel drug delivery systems for inflammatory bowel disease. World Journal of Gastroenterology, 28(18), 1922–1933. https://doi.org/10.3748/wjg.v28. i18.1922

Yoo, J.-W., Naeem, M., Choi, M., Cao, J., Yoon, S., Kim, M.-S., Jung, Y., Lee, J., Moon, H. R., Ikram, M., & Lee, Y. (2015). Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy. Drug Design, Development and Therapy, 3789. https://doi.org/10.2147/DDDT.S88672

Yu, Y. R., & Rodriguez, J. R. (2017). Clinical presentation of Crohn’s, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes. Seminars in Pediatric Surgery, 26(6), 349–355. https://doi.org/10.1053/j.sempedsurg.2017.10.003

Yuhara, H., Steinmaus, C., Cohen, S. E., Corley, D. A., Tei, Y., & Buffler, P. A. (2011). Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? American Journal of Gastroenterology, 106(11), 1911–1921. https://doi.org/10.1038/ajg.2011.301

Zhang, Q., Tao, H., Lin, Y., Hu, Y., An, H., Zhang, D., Feng, S., Hu, H., Wang, R., Li, X., & Zhang, J. (2016). A superoxide dismutase/catalase mimetic nanomedicine for targeted therapy of inflammatory bowel disease. Biomaterials, 105, 206–221. https://doi.org/10.1016/j. biomaterials.2016.08.010

Zhang, Y., Li, X., Zhou, Y., Wang, X., Fan, Y., Huang, Y., & Liu, Y. (2010). Preparation and evaluation of poly(ethylene glycol)–poly(lactide) micelles as nanocarriers for oral delivery of cyclosporine A. Nanoscale Research Letters, 5(6), 917–925. https://doi. org/10.1007/s11671-010-9583-4

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.